TNF-α activates phagocyte functions and facilitates granuloma formation and maintenance, and patients with autoimmune or chronic inflammatory diseases undergoing anti-TNF-α therapies have increased susceptibility for reactivation of latent tuberculosis or infection with nontuberculous mycobacteria (NTMs) (1, 2, 46, 47). The gene discussed is TNF; the disease is infection.